Immix Biopharma doses first patient in U.S. AL amyloidosis trial with NXC-201

Immix Biopharma announced that the first patient has been dosed at MSKCC in its U.S. NEXICART-2 trial with NXC-201, a sterically-optimized BCMA-targeted CAR-T cell therapy. The NEXICART-2 study is intended to evaluate the safety and efficacy of NXC-201 in relapsed/refractory AL Amyloidosis patients with adequate cardiac function who have not been exposed to prior BCMA-targeted therapy. The study builds on positive data from the initial ex-U.S. study, NEXICART-1, presented at the 27th Annual Meeting of The American Society of Gene and Cell Therapy which showed a 92% overall response rate in relapsed/refractory AL Amyloidosis patients. The best responder experienced a 28.0 month duration of response. “We believe initiation of the U.S. NEXICART-2 study is an important advancement in AL Amyloidosis. NXC-201 has the potential to become a first-in-class safe and durably-effective therapy for patients with relapsed/refractory AL Amyloidosis. We are humbled by the enthusiasm across the U.S. AL Amyloidosis community and look forward to robust enrollment for NEXICART-2,” said Ilya Rachman, M.D., Ph.D., CEO of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, “Dosing of the first patient in line with our mid-2024 guidance is a testament to the stellar execution of our extraordinary team and partners.”